I'm LongbridgeAI, I can summarize articles.Verastem reported a widened Q2 FY26 GAAP net loss of $34.7 million against revenue growth to $40.1 million, driven by increased R&D and commercial spending. The company ended the quarter with $136.4 million in cash, rising to $201.4 million pro forma after financing and milestones. Additionally, Verastem dosed the first patients in all three TARGET-D Phase 2 trials for VS-7375, with clinical data expected in October.
- Verastem posted Q2 GAAP net loss of $34.7 million, or $0.35 per share, versus a $25.9 million loss a year earlier. * Revenue climbed to $40.1 million from $2.1 million; net product revenue rose to $25.1 million from $2.1 million. * Operating expenses increased to $72.8 million from $45.9 million, driven by higher R&D costs and commercial operations spending. * Ended Q2 with $136.4 million in cash, cash equivalents and investments; pro forma cash was $201.4 million including $50 million Oberland financing and a $15 million COPIKTRA milestone. * First patients were dosed in all three TARGET-D Phase 2 trials for VS-7375; updated clinical data are expected in October, with enrollment completion targeted by year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061601BIZWIRE_USPR_____20260806_BW434497) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)